Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 5:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 209 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Recurrent Lung Adenocarcinoma Clear all
Completed Phase 1 Interventional

Specialized Radiation Therapy in Treating Patients With Stage II, Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer and Poor Performance Status

NCT00986297
View directory record Official record
Conditions
Lung Cancer
Interventions
hypofractionated radiation therapy
Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
2
States / cities
Stanford, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2020 · Synced Sep 23, 2026, 5:03 PM EDT
Completed Phase 2 Interventional Results available

Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers

NCT01935336
View directory record Official record
Conditions
Adenocarcinoma of the Lung, Extensive Stage Small Cell Lung Cancer, Limited Stage Small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent Small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
Ponatinib
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 10, 2022 · Synced Sep 23, 2026, 5:03 PM EDT
Completed No phase listed Observational

An Integrated Approach to Treating Recurrent Thoracic Carcinomas Resistant to Tyrosine Kinase Inhibitors

NCT02616211
View directory record Official record
Conditions
Adenocarcinoma of Lung, Lung Neoplasm, Cancer of Lung, Lung Cancer, Pulmonary Cancer, EGFR Genes, ALK Genes
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Sep 23, 2026, 5:03 PM EDT
Completed Phase 1 Interventional

Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors

NCT00667641
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Melanoma (Skin), Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
bortezomib, paclitaxel
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 9, 2011 · Synced Sep 23, 2026, 5:03 PM EDT
Completed Phase 1 Interventional

Inhaled Doxorubicin in Treating Patients With Primary Lung Cancer or Lung Metastases

NCT00004930
View directory record Official record
Conditions
Lung Cancer, Metastatic Cancer
Interventions
doxorubicin hydrochloride
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
2
States / cities
New York, New York • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Sep 23, 2026, 5:03 PM EDT
Completed Phase 2 Interventional Results available

Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

NCT00234052
View directory record Official record
Conditions
Lung Cancer
Interventions
bevacizumab, carboplatin, pemetrexed
Biological · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 120 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
5
States / cities
Chicago, Illinois • Evanston, Illinois • Harvey, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2019 · Synced Sep 23, 2026, 5:03 PM EDT
Completed Phase 2 Interventional

Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer

NCT00416650
View directory record Official record
Conditions
Lung Cancer
Interventions
erlotinib hydrochloride
Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2013
U.S. locations
4
States / cities
Chicago, Illinois • New York, New York • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2013 · Synced Sep 23, 2026, 5:03 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors

NCT00227617
View directory record Official record
Conditions
Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Lung Cancer, Neoplastic Syndrome, Neuroendocrine Tumor
Interventions
bevacizumab, 5-fluorouracil, leucovorin, oxaliplatin
Biological · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
2
States / cities
San Francisco, California • Vallejo, California
Source: ClinicalTrials.gov public record
Updated May 21, 2023 · Synced Sep 23, 2026, 5:03 PM EDT
Recruiting Phase 1 Interventional

A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer

NCT07227168
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma HNSCC, Non-Small Cell Lung Cancer NSCLC, Esophageal Cancer, Gastric Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma (PDAC), Cervical Cancer, Endometrial Cancer, Urothelial Cancer
Interventions
STRO-004, Pembrolizumab
Drug
Lead sponsor
Sutro Biopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
9
States / cities
San Diego, California • Denver, Colorado • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 23, 2026, 5:03 PM EDT
Completed Phase 2 Interventional

A Study of the Safety and Effects of ADH-1 Given Intravenously as a Single Agent

NCT00264433
View directory record Official record
Conditions
Neoplasms
Interventions
ADH -1 (Exherin™)
Drug
Lead sponsor
Adherex Technologies, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
5
States / cities
Fort Myers, Florida • Chapel Hill, North Carolina • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2007 · Synced Sep 23, 2026, 5:03 PM EDT
Completed Phase 1Phase 2 Interventional

Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer

NCT00002577
View directory record Official record
Conditions
Lung Cancer
Interventions
radiation therapy
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
224
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 175 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2013 · Synced Sep 23, 2026, 5:03 PM EDT
Withdrawn Phase 1 Interventional

Dynamic Contrast Enhanced MRI in Patients With Advanced Breast or Pancreatic Cancer With Metastases to the Liver or Lung

NCT01741597
View directory record Official record
Conditions
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Liver Metastases, Lung Metastases, Recurrent Breast Cancer, Recurrent Pancreatic Cancer, Stage IV Breast Cancer, Stage IV Pancreatic Cancer
Interventions
dynamic contrast-enhanced magnetic resonance imaging, pharmacological study, tumor-homing peptide iRGD
Procedure · Other · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated May 29, 2014 · Synced Sep 23, 2026, 5:03 PM EDT
Completed Phase 2 Interventional Results available

Topotecan and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Did Not Respond to Previous Systemic Chemotherapy

NCT00365547
View directory record Official record
Conditions
Lung Cancer
Interventions
bevacizumab, topotecan hydrochloride
Biological · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Minneapolis, Minnesota • Saint Louis Park, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 27, 2017 · Synced Sep 23, 2026, 5:03 PM EDT
Completed Phase 1 Interventional

Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

NCT01204476
View directory record Official record
Conditions
Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor, Metastatic Digestive System Neuroendocrine Tumor G1, Pancreatic Glucagonoma, Pancreatic Insulinoma, Pancreatic Polypeptide Tumor, Paraganglioma, Recurrent Digestive System Neuroendocrine Tumor G1, Recurrent Merkel Cell Carcinoma, Recurrent Pancreatic Neuroendocrine Carcinoma, Regional Digestive System Neuroendocrine Tumor G1, Somatostatin-Producing Neuroendocrine Tumor, Stage III Merkel Cell Carcinoma, Stage IV Merkel Cell Carcinoma, Thyroid Gland Medullary Carcinoma
Interventions
Cixutumumab, Everolimus, Laboratory Biomarker Analysis, Octreotide Acetate, Pharmacological Study
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Sep 23, 2026, 5:03 PM EDT
Completed Phase 2 Interventional Results available

Cryotherapy and GM-CSF in Treating Patients With Lung Metastases or Primary Lung Cancer

NCT00514215
View directory record Official record
Conditions
Kidney Cancer, Lung Cancer, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
sargramostim, flow cytometry, immunoenzyme technique, biopsy, cryosurgery
Biological · Other · Procedure
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Sep 23, 2026, 5:03 PM EDT
Completed Phase 3 Interventional

Combination Chemotherapy With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

NCT00006484
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, paclitaxel, tirapazamine
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
93
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2013 · Synced Sep 23, 2026, 5:03 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Sorafenib and High-Dose Carboplatin, Paclitaxel, and External-Beam Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

NCT00547443
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, paclitaxel, sorafenib tosylate, radiation therapy
Drug · Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Arlington, Texas • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Sep 23, 2026, 5:03 PM EDT
Terminated Phase 1 Interventional

Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer

NCT00002947
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Childhood Langerhans Cell Histiocytosis, Gastrointestinal Carcinoid Tumor, Head and Neck Cancer, Intraocular Melanoma, Islet Cell Tumor, Kidney Cancer, Lung Cancer, Melanoma (Skin), Neoplastic Syndrome, Neuroendocrine Carcinoma of the Skin, Pheochromocytoma
Interventions
indium In 111 pentetreotide
Radiation
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2004
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 1, 2014 · Synced Sep 23, 2026, 5:03 PM EDT
Terminated Phase 2 Interventional Results available

Conformal Radiation Therapy in Treating Patients With Metastatic Cancer Outside the Brain

NCT00550654
View directory record Official record
Conditions
Kidney Cancer, Melanoma (Skin), Metastatic Cancer, Ovarian Cancer, Sarcoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
questionnaire administration, 3-dimensional conformal radiation therapy, hypofractionated radiation therapy, image-guided radiation therapy, tomotherapy
Other · Radiation
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Sep 23, 2026, 5:03 PM EDT
Completed Phase 2 Interventional

Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer

NCT00096083
View directory record Official record
Conditions
Cancer
Interventions
isolated perfusion, melphalan
Drug
Lead sponsor
Delcath Systems Inc.
Industry
Eligibility
16 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 22, 2013 · Synced Sep 23, 2026, 5:03 PM EDT
Completed Phase 2 Interventional Results available

S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00661193
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, erlotinib hydrochloride, paclitaxel
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
124
States / cities
Little Rock, Arkansas • Antioch, California • Berkeley, California + 90 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Sep 23, 2026, 5:03 PM EDT
Completed Phase 1 Interventional

Biological Therapy in Treating Patients With Metastatic Cancer

NCT00004604
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Head and Neck Cancer, Liver Cancer, Lung Cancer, Metastatic Cancer, Ovarian Cancer, Pancreatic Cancer, Testicular Germ Cell Tumor
Interventions
CEA RNA-pulsed DC cancer vaccine
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 21, 2013 · Synced Sep 23, 2026, 5:03 PM EDT
Completed Phase 1 Interventional

Thalidomide and Docetaxel in Treating Patients With Advanced Cancer

NCT00049296
View directory record Official record
Conditions
Cancer
Interventions
docetaxel, thalidomide
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 10, 2010 · Synced Sep 23, 2026, 5:03 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

NCT05150691
View directory record Official record
Conditions
HER2-positive Advanced Solid Tumor
Interventions
DB-1303/BNT323, Pertuzumab Injection, Ritonavir, Itraconazole
Biological · Drug
Lead sponsor
DualityBio Inc.
Industry
Eligibility
18 Years and older
Enrollment
796 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
35
States / cities
Cerritos, California • Los Angeles, California • San Diego, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 23, 2026, 5:03 PM EDT